Compounded GLP-1s: the cheap era is ending — be careful
Short answer: Compounded semaglutide and tirzepatide — the low-cost copies sold by telehealth firms and med spas during the shortage years — are being phased out: the FDA acted in 2026 to remove both molecules from bulk-compounding eligibility. If you have Medicare and qualify for the $50 Bridge, you have a safer, cheaper option than anything the compounding market ever offered.
Program facts last verified against CMS: July 21, 2026
How we got here
During the 2023–2024 shortages, compounding pharmacies could legally produce versions of semaglutide and tirzepatide, and an industry of cheap online prescribing grew around that exception. The shortages ended, the legal basis narrowed, and in 2026 the FDA moved to exclude these molecules from the bulk-compounding list — the pathway that made mass-market compounded GLP-1s possible. Offers still circulating exist in a shrinking, murkier legal space.
The practical risks were never just legal: compounded products aren't FDA-approved, dosing errors drove real hospitalizations, and product quality varied by pharmacy. For a Medicare-age population managing other conditions and medications, those risks weigh heavier.
The better answer for Medicare members
At $50/month, the Bridge undercuts what compounders ever charged — for the genuine, FDA-approved product with a prescriber and prior authorization attached. If you're being pitched compounded GLP-1s and you have Medicare, run the eligibility check first; the legitimate path is likely cheaper than the gray-market one.
Take the 2-minute eligibility check →
Common questions
Is compounded semaglutide illegal now?
The bulk-compounding pathway that enabled mass production is ending per FDA action in 2026. Narrow patient-specific compounding exceptions exist, but the mass-market offers are winding down and operate in an increasingly gray space.
I'm mid-course on a compounded product. What now?
Talk to your prescriber about transitioning to an approved product — and if you're on Medicare, check your Bridge eligibility; the $50 path may cost less than your compounded subscription did.
Does Medicare ever cover compounded GLP-1s?
No. The Bridge covers three FDA-approved products (Wegovy, Zepbound KwikPen, Foundayo), and standard Part D covers approved products on plan formularies.
Related
Program-fact sources: CMS — Medicare GLP-1 Bridge · KFF